Salem, NH, United States
Salem, NH, United States
SEARCH FILTERS
Time filter
Source Type

WEST BLOOMFIELD, Mich. & SALEM, N.H.--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that the Henry Ford Cancer Institute has installed Gamma Medica’s LumaGEM® Molecular Breast Imaging system, which is the first MBI machine in Michigan. MBI is a proven, effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection of breast cancer in women.1 The new system can be found at the Henry Ford West Bloomfield Hospital where it will provide diagnostic and secondary screenings to women who have a higher risk of breast cancer and with dense breast tissue. Approximately 50 percent of U.S. women are reported to have dense breast tissue. Unfortunately, many do not realize that they have dense tissue, or the implications dense breast tissue has on increasing their lifetime risk of breast cancer.2 Additionally, both dense breast tissue and cancer appear white on mammograms, making it difficult to distinguish between the two. It’s like trying to find a snowflake in a snowstorm, which can lead to false negatives or delayed diagnoses.3 “The new installation of the LumaGEM MBI system at the Henry Ford Cancer Institute gives women in Michigan and surrounding areas access to a clinically superior diagnostic and secondary breast screening method,” said Philip Croxford, president and CEO of Gamma Medica. “We are delighted to be able to partner with the Henry Ford Cancer Institute and look forward to collaborating with them to help improve early cancer detection for women who are at greater risk. We believe MBI will ensure that more women have the opportunity to receive personalized breast screenings and improved clinical outcomes.” A prospective study conducted by the Mayo Clinic in Rochester, MN found that the addition of MBI to mammography significantly increased the detection of breast cancer in women with dense breast tissue.4 The following year, a retrospective clinical study published in the American Journal of Roentgenology’s August 2016 issue confirmed these findings. This study involved nearly 1,700 women with dense breast tissue over a three year period and found that LumaGEM had an incremental cancer detection rate of 7.7 cancers per thousand (7.7/1000) over mammography (which detects 3.0/1000 alone). Approximately 85 percent of the cancers found in the study were confirmed to be invasive, of which 82 percent were node negative, indicating they were detected at an early stage and therefore presented a better prognosis.5 Clinical research also showcases that the use of LumaGEM reduces biopsies, often painful and costly, by 50 percent, compared to other modalities.6 The MBI procedure requires minimal breast compression; patients are able to sit comfortably throughout the exam and results are typically available the same day. “The Henry Ford Cancer Institute offers some of the most advanced screening options available to our patients, and this technology brings added imaging capability for women with dense breast tissue,” says Patricia Miller, M.D., director of Breast Imaging at Henry Ford West Bloomfield Hospital. The new technology was made possible by philanthropic support and donations. About Gamma Medica, Inc. Gamma Medica, Inc. is a women’s health company focused on overcoming the limitations of anatomical imaging experienced by mammography and other screening modalities in the early detection of breast cancer. The company’s LumaGEM® MBI system is the first commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. For more information visit, www.gammamedica.com. About the Henry Ford Cancer Institute The Henry Ford Cancer Institute is one of the largest cancer programs in Michigan, providing care at four hospitals and four outpatient facilities throughout southeast Michigan. Treatment for the most complex or rare cancers and the Institute’s extensive cancer research program is anchored by Henry Ford Hospital. For more information, visit www.henryford.com/cancer. 1 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251. 2 Mandelson MT, et al. J Natl Cancer Inst. 2000; 92: 1081-7 3 Mayo Clinic. Tests and Procedures Mammogram. http://www.mayoclinic.org/tests-procedures/mammogram/in-depth/dense-breast-tissue/art-20123968?pg=2 4 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251. 5 Shermis, RB, Wilson, K, et al. Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue. American Journal of Roentgenology. August 2016. 6 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251.


Global Breast Imaging Market Shows Positive Signs of Growth During the Forecast Period 2017-2022 Breast imaging is the screening of the breast to detect cancer at various levels. The report highlights a significant growth for the market at a positive CAGR during the forecast period 2017-2022. Albany, NY, May 06, 2017 --( Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1037516 Breast imaging is the screening of the breast to detect cancer at various levels. Breast cancer is a major type of cancer which is the cause of a mass death percentage; therefore, its early detection and effective medication need to be done with proper awareness to eradicate the problem. Breast imaging may range from Mammography, Tomosynthesis, Xeromammography, Galactography, Breast MRI, Breast ultrasound and others. The report starts with the overview of breast imaging market detailing product overview and its scope. The report further segments the market by breast imaging types such as analog breast imaging equipment and digital breast imaging equipment, providing comparison analysis of their production, CAGR and market share. Breast imaging application is also reported with their consumption comparison for the period 2012-2022. The applications listed include- General Surgery, Breast Surgery, and Physical examination. On the geographical scale, global breast imaging market is compared for market status and prospect for 2012-2022. The regions compared in the report include North America, Europe, China, Japan, Southeast Asia and India. Further, the breast imaging market competition is reported on the global scale for 2012-2017, along with its concentration rate, mergers & acquisitions, and expansion. Top players in the field include: · GE Healthcare · Siemens · Hologic · Philips Healthcare · Toshiba · Dilon Technologies · Gamma Medica · Sonocine · Fujifilm · Aurora Imaging Technology Further, a detailed comparison analysis is done to display supply, consumption, export, import by region; production, revenue, price trend by type and lastly market share, growth rate, market drivers & opportunities by the application. Browse Full Report with TOC: http://www.marketresearchhub.com/report/global-breast-imaging-market-research-report-2017-report.html The report concludes by offering breast imaging manufacturing cost analysis covering key raw material, price trend and proportion of manufacturing cost structure. Moreover, details of raw material, labor cost and manufacturing expenses can also be analyzed. The reader can also learn about the future consequences that may affect the market growth. These are mentioned under market effect factors analysis that constitutes technology risk, consumer preference change and environmental/political environmental change. About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Details: 90 State Street, Albany, NY 12207, United States Toll Free: 866-997-4948 (US-Canada) Tel: +1-518-621-2074 Email: press@marketresearchhub.com Website: http://www.marketresearchhub.com/ Follow Us on: Twitter: https://twitter.com/MktResearchHub/ LinkedIn: https://www.linkedin.com/company/market-research-hub/ Facebook: https://www.facebook.com/MarketResearchHub/ Albany, NY, May 06, 2017 --( PR.com )-- The surging unhealthy lifestyle of the young generation and effects of adulteration, have led to the rising number of breast cancer problems at the global level. To give detailed insight and forecasted growth of the breast imaging market, Market Research Hub (MRH) has added a report titled “Global Breast Imaging Market Research Report 2017” to its wide database. The report highlights a significant growth for the market at a positive CAGR during the forecast period 2017-2022.Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1037516Breast imaging is the screening of the breast to detect cancer at various levels. Breast cancer is a major type of cancer which is the cause of a mass death percentage; therefore, its early detection and effective medication need to be done with proper awareness to eradicate the problem. Breast imaging may range from Mammography, Tomosynthesis, Xeromammography, Galactography, Breast MRI, Breast ultrasound and others.The report starts with the overview of breast imaging market detailing product overview and its scope. The report further segments the market by breast imaging types such as analog breast imaging equipment and digital breast imaging equipment, providing comparison analysis of their production, CAGR and market share. Breast imaging application is also reported with their consumption comparison for the period 2012-2022. The applications listed include- General Surgery, Breast Surgery, and Physical examination.On the geographical scale, global breast imaging market is compared for market status and prospect for 2012-2022. The regions compared in the report include North America, Europe, China, Japan, Southeast Asia and India. Further, the breast imaging market competition is reported on the global scale for 2012-2017, along with its concentration rate, mergers & acquisitions, and expansion. Top players in the field include:· GE Healthcare· Siemens· Hologic· Philips Healthcare· Toshiba· Dilon Technologies· Gamma Medica· Sonocine· Fujifilm· Aurora Imaging TechnologyFurther, a detailed comparison analysis is done to display supply, consumption, export, import by region; production, revenue, price trend by type and lastly market share, growth rate, market drivers & opportunities by the application.Browse Full Report with TOC: http://www.marketresearchhub.com/report/global-breast-imaging-market-research-report-2017-report.htmlThe report concludes by offering breast imaging manufacturing cost analysis covering key raw material, price trend and proportion of manufacturing cost structure. Moreover, details of raw material, labor cost and manufacturing expenses can also be analyzed. The reader can also learn about the future consequences that may affect the market growth. These are mentioned under market effect factors analysis that constitutes technology risk, consumer preference change and environmental/political environmental change.About Market Research Hub:Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Details:90 State Street,Albany, NY 12207,United StatesToll Free: 866-997-4948 (US-Canada)Tel: +1-518-621-2074Email: press@marketresearchhub.comWebsite: http://www.marketresearchhub.com/Follow Us on:Twitter: https://twitter.com/MktResearchHub/LinkedIn: https://www.linkedin.com/company/market-research-hub/Facebook: https://www.facebook.com/MarketResearchHub/ Click here to view the list of recent Press Releases from Market Research Hub


— Global Gamma Camera Industry Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight. Companies profiled in this report are GE, Philips, Siemens, Digirad, Mediso, MIE, DDD Diagnostic, Dilon Technologies, Gamma Medica, Capintec, Beijing Hamamatsu, Basda in terms of Basic Information, Manufacturing Base, Sales Area and Its Competitors, Sales, Revenue, Price and Gross Margin (2012-2017). Split by Product Types, with sales, revenue, price, market share of each type, can be divided into • Large type • Small type Split by applications, this report focuses on sales, market share and growth rate of Gamma Camera in each application, can be divided into • Thyroid scanning • Molecular breast imaging • Kidney scanning Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/482445 Table of Content: 1 Gamma Camera Market Overview 2 Global Gamma Camera Sales, Revenue (Value) and Market Share by Manufacturers 3 Global Gamma Camera Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 4 Global Gamma Camera Manufacturers Profiles/Analysis 5 North America Gamma Camera Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 6 Latin America Gamma Camera Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 7 Europe Gamma Camera Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 8 Asia-Pacific Gamma Camera Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 9 Middle East and Africa Gamma Camera Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 10 Gamma Camera Manufacturing Cost Analysis 11 Industrial Chain, Sourcing Strategy and Downstream Buyers 12 Marketing Strategy Analysis, Distributors/Traders 13 Market Effect Factors Analysis 14 Global Gamma Camera Market Forecast (2017-2022) 15 Research Findings and Conclusion 16 Appendix Inquire more for more details about this report at: https://www.themarketreports.com/report/ask-your-query/482445 For more information, please visit https://www.themarketreports.com/report/2017-2022-global-top-countries-gamma-camera-market-report-4095039


SALEM, N.H. & PHILADELPHIA--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Einstein Medical Center Philadelphia has installed Pennsylvania’s first clinical LumaGEM® Molecular Breast Imaging system. MBI is a proven, effective supplementary screening method to standard mammography and/or tomosynthesis (3D mammography), significantly increasing early detection of breast cancer in women.1 In the U.S., approximately 50 percent of women are reported to have dense breast tissue, but many women do not realize they have dense breasts or the implications dense breast tissue has on increasing their lifetime risk of breast cancer.2 Dense breast tissue and cancer both appear white on mammograms making it difficult to distinguish between the two. It’s like trying to find a snowflake in a snowstorm, which can lead to false negatives or delayed diagnoses.3 “The new installation of the LumaGEM MBI system at Einstein Medical Center Philadelphia now gives women access to a clinically superior diagnostic and secondary breast screening method,” said Philip Croxford, president and CEO of Gamma Medica. “LumaGEM MBI provides the opportunity for personalized breast screenings in women who are at higher risk of being diagnosed with breast cancer, in effect raising the standard in breast cancer detection. We look forward to continued collaboration with the hospital and its affiliates with the goal of improving the lives of women in the area.” A breakthrough retrospective clinical study published in the August issue of the American Journal of Roentgenology confirmed MBI’s high incremental cancer detection rate: MBI was able to detect 7.7 cancers per 1,000 women screened that were not found using mammography. Approximately 85 percent of these cancers were invasive and 82 percent of the invasive cancers were also node negative, meaning they were detected at an earlier stage and presented a better prognosis. 4 While mammograms may fail to detect breast tumors due to tissue density, MBI highlights metabolic activity in these tumors despite breast density, leading to an earlier diagnosis. “I’m excited about adding this technology to our program so we can help screen so many of our patients who have dense breast tissue,” said Debra Somers Copit, MD, director of breast imaging for Einstein Healthcare Network. About Gamma Medica, Inc. Gamma Medica, Inc. is a women’s health company focused on overcoming the limitations of anatomical imaging experienced by mammography and other screening modalities in the early detection of breast cancer. The company’s LumaGEM® MBI system is the first commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. For more information visit, www.gammamedica.com. About Einstein Healthcare Network Einstein Healthcare Network is a 1,044-bed integrated delivery network with more than 8,500 employees serving the communities of Philadelphia and Montgomery County, Pa. Einstein Medical Center Philadelphia is the largest independent academic medical center in the Philadelphia region training over 3,500 health professional students each year with 400 residents in more than 30 accredited programs. The network also provides a comprehensive range of healthcare services through Einstein Medical Center Elkins Park, Einstein Medical Center Montgomery, MossRehab, Willowcrest, outpatient care centers, and a network of more than 700 primary care physicians and specialists throughout the region. For more information, visit www.einstein.edu or call 1-800-EINSTEIN. 1 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2 Mandelson MT, et al. J Natl Cancer Inst. 2000; 92: 1081-7 3 Mayo Clinic. Tests and Procedures Mammogram. http://www.mayoclinic.org/tests-procedures/mammogram/in-depth/dense-breast-tissue/art-20123968?pg=2 4 Shermis, RB, Wilson, K, et al. Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue. American Journal of Roentgenology. August 2016.


SALEM, N.H. & PHILADELPHIA--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Einstein Medical Center Philadelphia has committed to purchase Pennsylvania’s first clinical LumaGEM® Molecular Breast Imaging system. MBI is a secondary screening and diagnostic tool that is particularly useful for women who have dense breast tissue and women with a high risk of being diagnosed with cancer. It is a proven, effective supplementary screening meth


SALEM, N.H.--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced it has partnered with Hospital Services Limited (HSL), an established medical device company that distributes, installs and services radiology capital equipment and medical devices. This partnership will provide women with dense breast tissue access to Gamma Medica’s LumaGEM® Molecular Breast Imaging system in the United Kingdom, Ireland and the Channel Islands. Women are eligible for the United Kingdom’s NHS breast screening programme at age 50-79 years, with women being invited to be screened every three years.1 Similarly in Ireland, women 50-69 years-old are eligible for breast screenings every two years.2 Dense breast tissue not only increases the risk of developing breast cancer, but decreases the visibility of a cancer on conventional mammograms and other forms of anatomical imaging devices. Dense breast tissue and cancer both appear white on mammograms making it difficult to distinguish between the two—it’s like trying to find a snowflake in a snowstorm. This may lead to false negatives, unwarranted biopsies or delayed diagnoses.3 Ideal for dense breast tissue, MBI is a groundbreaking technology that significantly improves early detection of breast cancer in women with dense breast tissue. The technology has proven to be as effective as a secondary screening method compared to ultrasound or MRI with far fewer false positives.4 Peer-reviewed clinical research reports the use of LumaGEM MBI reduces the need for tissue biopsies by 50 percent compared to other modalities.4 MBI is also more comfortable and better tolerated by most patients than conventional mammography or MRI. “We are pleased that through our collaboration with HSL, women with dense breasts in the UK, Ireland and the Channel Islands, will soon have access to the LumaGEM MBI technology,” said Philip Croxford, Gamma Medica President and CEO. “This partnership is the first step in Gamma Medica’s global expansion to increase awareness and access to clinical superior breast imaging technology worldwide. Leveraging HSL’s network enables Gamma Medica to continue to promote early detection on an international scale.” A breakthrough retrospective study, which complemented earlier published prospective clinical research, was published in the American Journal of Roentgenology’s August issue.5 This retrospective study monitored over 1,700 women with dense breast tissue over a three-year period. The study confirmed LumaGEM’s additional cancer detection rate of 7.7 cancers per 1,000, an increase from three cancers per 1,000 with mammography alone. The study also concluded that of the additional breast cancers found, approximately 85 percent of these cancers were invasive and node negative, indicating they were detected at an early stage and therefore presented the patient with the likelihood of a better prognosis.6 “Hospital Services Limited distributes market-leading technology and we are thrilled to add Gamma Medica’s LumaGEM Molecular Breast Imaging to our product offerings for our clients,” said Dominic Walsh, CEO of Hospital Services Limited. “Introducing Gamma Medica to the European market will enable women outside of the United States to receive the early detection technology they need. We’re excited to be Gamma Medica’s partner in this endeavor.” Gamma Medica launched the Be Certain campaign in the United States to raise awareness about breast density and breast cancer screening options. By sharing patient and physician testimonials, breast density facts and statistics and the latest news relating to breast density and breast screenings, the educational website aims to provide the most accurate information for physicians, patients and caregivers. For more information about breast density and screening options, visit www.becertain.info. About Gamma Medica, Inc. Gamma Medica, Inc. is a women’s health company focused on overcoming the limitations of anatomical imaging experienced by mammography and other screening modalities in the early detection of breast cancer. The company’s LumaGEM® MBI system is the first commercially available, FDA-cleared, fully solid-state digital imaging system utilizing dual-head Digital Direct Conversion Gamma Imaging™ (DDCGI™) technology for molecular breast imaging. With over 90 percent sensitivity and specificity, LumaGEM MBI has been shown to significantly improve cancer detection in women with dense breast tissue with fewer false positives relative to anatomical imaging technologies, such as MRI and whole breast ultrasound. For more information visit, www.gammamedica.com. About Hospital Services Limited Hospital Services Limited (HSL) is a leading provider of products & services to the healthcare sector in both Ireland and the UK. HSL’s Radiology division has over 50 years’ experience working within this diagnostic imaging arena. HSL offers unprecedented levels of quality products, services and technical assistance. HSL representatives with extensive imaging experience, supply products and support to all levels of medical staff with a major focus on providing quality service to the individual customer, whilst manufacturer trained engineers ensure equipment is maintained to exacting standards. HSL is committed to sourcing the latest technologies available to help provide peace of mind to patients and physicians alike while utilising cutting edge diagnostic tools. 1 Gov.uk, Breast Screening: Programme Overview, 2015. https://www.gov.uk/guidance/breast-screening-programme-overview 2 BreastCheck. http://www.breastcheck.ie/ 3 Mayo Clinic. Tests and Procedures Mammogram. http://www.mayoclinic.org/tests-procedures/mammogram/in-depth/dense-breast-tissue/art-20123968?pg=2 4 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251. 5 Rhodes DJ, Hruska CB, Conners AL, et al. JOURNAL CLUB: Molecular Breast Imaging at Reduced Radiation Dose for Supplemental Screening in Mammographically Dense Breasts. American Journal of Roentgenology. 2015;204(2):241-251. 6 Shermis RB, Wilson KD, Doyle MT, Martin TS, Merryman D, Kudrolli H, Brenner RJ. Supplemental Breast Cancer Screening with Molecular Breast Imaging for Women with Dense Breast Tissue. American Journal of Roentgenology. 2016;207: 1-8. doi:10.2214/AJR15.15924.


CHICAGO--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced several 2016 achievements for its LumaGEM Molecular Breast Imaging system at this year’s Radiological Society of North America (RSNA) annual meeting (booth #2871). Over the past year, this MBI system has grown in national prominence and expanded its user base through a major educational campaign on breast density called Be Certain and by driving irrefutable clinical results featured in


News Article | November 1, 2016
Site: www.newsmaker.com.au

Mammography refers to a standard diagnostic and screening technique that is used to screen breast tissues for the presence of malignant tumor. Mammography involves the use of low-energy X-rays for early detection of breast cancer. On the basis of technology used, the mammography market can be classified as film-screen or digital. Initially, conventional screen-film mammography (SFM) was the only technique available in the market, which involved high-spatial resolution for producing images. Film cassettes are used in screen-film mammography, while electronic x-ray detectors are used in digital mammography; better images can be obtained using the latter. In digital mammography, photons are converted to light, which travels to a device that converts this into a digital signal to display on a computer monitor. The global market for mammography is expected to increase at a significant rate. This is due to increasing prevalence of breast cancer cases and rising awareness about the same. The market for mammography is highly regulated. Various acts have been passed worldwide, such as the Mammography Quality Standards Act (MQSA) to ensure good quality care in mammography. North America dominates the global market for mammography due to technical advancements in the field of diagnostic imaging and high prevalence of breast cancer in the region. Moreover, increased awareness about advantages of cancer detection in early stages and improved healthcare facilities are driving the market for mammography in North America. Over the next few years, the market for mammography in Asia is expected to experience high growth rate, followed by that in Europe. China and India are expected to be the fastest growing markets in Asia. This is due to the large population base and increasing prevalence of breast cancer cases in these countries. Some of the key driving forces of the mammography market in emerging economies are increasing awareness and improved healthcare facilities. Elderly people and patients suffering from hormonal disorders are at high risk of breast cancer. For instance, menopausal hormone therapy increases risk of breast cancer. Various factors such as rising geriatric population and increasing number of cases of hormonal misbalances are expected to drive the global market for mammography. Moreover, increasing awareness about mammography techniques is expected to drive this market. However, factors such as lack of awareness, discomfort to the patients, and side effects associated with mammography are restraining the market growth. Furthermore, lack of accurate results is also limiting the growth of the global market for mammography. Growing demographics and economies in developing countries such as India and China are expected to offer good opportunities for the global mammography market. This is due to increasing awareness and rising adoption rate of mammography techniques in these regions. Innovative new products with fewer side effects are expected to drive the global mammography market. However, changing health regulations imposed by various governments and availability issues could be major challenges for this market. Rising number of mergers and acquisitions and new product launches are some of the latest trends in the global mammography market. Major companies in the global mammography market include GE Healthcare, Koninklijke Philips N.V., Hologic, Inc and Gamma Medica, Inc. Some other companies having significance presence in this market are Siemens Healthcare, Toshiba Corporation, and SonoCiné, Inc.


WEST BLOOMFIELD, Mich. & SALEM, N.H.--(BUSINESS WIRE)--Gamma Medica, a leader in molecular breast imaging (MBI) technology, today announced that Henry Ford Health System has purchased Gamma Medica’s LumaGEM Molecular Breast Imaging system. The system is set to be installed by the end of 2016 at Henry Ford West Bloomfield Hospital. The MBI technology will be offered as a secondary screening and diagnostic tool following X-ray mammography, particularly for women with dense breast tissue. This pro


A calibration rig and calibration method for an imaging system includes a base and a holder extending from the base, the holder including a fixture configured to hold a radioactive source material in a two-dimensional geometric configuration and a radioactive source material disposed in the fixture.

Loading Gamma Medica collaborators
Loading Gamma Medica collaborators